Stocks / Stock overview

Iovance Biotherapeutics, Inc. (IOVA)

$10.64+4.42%Aft $10.61 (-0.28%)Market cap $4.82B

NasdaqGM · Price as of · Delayed Quote

Stock Scorer
Scoring…
Analyst consensus
Buy$10.22
  • Analysts9
  • Implied upside-3.9%
  • Target range$6.00 to $15.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
November 5, 2026before the open
  • EPS expected-$0.10
  • A year ago-$0.25
  • Revenue expected$110.1M +63%
  • Estimate range-$0.12 to -$0.08
Consensus of 7 analysts for the quarter ending September 30, 2026. Beat the estimate in 2 of the last four quarters. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
4September 10, 2026OWNERSHIP DOCUMENT
4September 10, 2026OWNERSHIP DOCUMENT
4September 10, 2026OWNERSHIP DOCUMENT
4September 3, 2026OWNERSHIP DOCUMENT
4September 3, 2026OWNERSHIP DOCUMENT
4September 3, 2026OWNERSHIP DOCUMENT
4August 12, 2026OWNERSHIP DOCUMENT
4August 10, 2026OWNERSHIP DOCUMENT
All SEC filings

Articles that mention Iovance Biotherapeutics without it being the main subject.

Claude stock trades week 11: it bought Grab (GRAB) because the CEO did
Columns

Claude stock trades week 11: it bought Grab (GRAB) because the CEO did

Claude's most recent trade is Grab, bought this morning after the CEO spent nearly $30 million of his own money on the stock. It now holds two stocks at once for the first time, and it is still down 26%.

Sep 22, 2026

Frequently asked questions

When does IOVA report earnings?

Iovance Biotherapeutics, Inc. (IOVA) is scheduled to report quarterly results on November 5, 2026, before the open. The 7-analyst consensus is -$0.10 per share on revenue of $110.1M for the quarter ending September 30, 2026, against -$0.25 and $67.5M a year earlier. It has beaten the consensus EPS estimate in 2 of the last four quarters.

What do analysts expect for IOVA?

9 analysts cover Iovance Biotherapeutics, Inc. (IOVA). The consensus rating is Buy. The average price target is $10.22, in a range of $6.00 to $15.00.

Are insiders buying or selling IOVA?

We have no qualifying Form 4 insider purchases or sales on record for Iovance Biotherapeutics, Inc. (IOVA). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see IOVA SEC filings?

Recent filings are listed on this page, newest first. The latest is a 4 filed September 10, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.